Cheng, Li
Li, Yichao http://orcid.org/0000-0001-5791-096X
Qi, Qian
Xu, Peng
Feng, Ruopeng
Palmer, Lance http://orcid.org/0000-0002-2519-8602
Chen, Jingjing
Wu, Ruiqiong
Yee, Tiffany
Zhang, Jingjing
Yao, Yu
Sharma, Akshay http://orcid.org/0000-0003-3281-2081
Hardison, Ross C. http://orcid.org/0000-0003-4084-7516
Weiss, Mitchell J. http://orcid.org/0000-0003-2460-3036
Cheng, Yong http://orcid.org/0000-0002-9314-0971
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35GM133614)
U.S. Department of Health & Human Services | National Institutes of Health (R24DK106766, R24DK106766, R24DK106766)
Article History
Received: 7 August 2020
Accepted: 30 March 2021
First Online: 6 May 2021
Competing interests
: M.J.W. is a consultant for Cellarity and Novartis and has equity in Beam Therapeutics (a base-editing company). A.S. is the St. Jude Children’s Research Hospital site principal investigator of clinical trials for genome editing of SCD, sponsored by Vertex Pharmaceuticals/CRISPR Therapeutics (ExternalRef removed) and Novartis (ExternalRef removed). The industry sponsors provide funding for the clinical trial, which includes salary support paid to the institution of A.S. A.S. is also a consultant for Spotlight Therapeutics.